Pall Corp’s Biotech business has entered a strategic partnership with Aetos Biologics a biosimilar cell line development company, to offer biosimilar manufacturing solutions. Pall Biotech will provide access to next generation bioprocess equipment, such as the Allegro STR Single-use Stirred Tank Bioreactor for GMP manufacturing, and consumables for biosimilar production. Aetos Biologics will provide high-quality/high-titer cell lines, and scalable manufacturing processes.

“Biosimilars are a replication of a successful biopharmaceutical product. While they are much less expensive than innovator molecules, the complexities in their development make it critical to work with the right equipment and service providers,” said Mario Philips, vice president and general manager at Pall Biotech. “We are excited to partner with the Aetos Biologics team to advance the market impact of biosimilars and deliver lower priced, high-quality options to end users.”

“Our team is constantly working to optimize a growing pipeline of high-yield biosimilars with outstanding quality,” said Amita Goel, founder and chief executive officer of Aetos Biologics. “Through this strategic partnership with Pall Biotech, we can ensure that the exceptional quality we achieve in scaled-up processes is efficiently transferred and reproduced by the client.”